The plasma insulin or C-peptide response to a 90-min constant glucose infusion 5 mg. kg ideal body weight-~, min-1 provides Beta-cell assessment comparable to more intensive methods. In 14 diet-treated Type 2 (non-insulin-dependent) diabetic subjects and 12 non-diabetic subjects, plasma insulin and C-peptide concentrations gave near linear plots against simultaneous glucose values. The 'glucose-insulin and glucose-C-peptide vectors' (G-I and G-C vectors), could be extrapolated to predict insulin and C-peptide levels during a 12 mmol/1 hyperglycaemic clamp. Predicted concentrations correlated with clamp concentrations, r = 0.94 and r = 0.98 respectively, p < 0.001, validating the vectors as empirical glucose dose-response curves. The vector slopes correlated highly with %Beta, a mathematical model-derived measure of Beta-cell function using constant infusion of glucose model assessment, Spearman r = 0.95 and 0.93 for insulin and C-peptide, respectively. G-I vector slopes in 21 diet-treated Type 2 diabetic subjects with fasting glucose (mean + 1 SD) 7.5 + 2.3 mmol/1, were lower than in 28 non-diabetic subjects, (geometric mean, 1 SD range, 8.4 pmol/mmol (3.3-21.0) and 25.1 pmol/mmol (14.3-44.1), p < 0.001, respectively), indicating an impaired Beta-cell response. The G-I vector slopes correlated with obesity in both groups (r = 0.54 p < 0.02 and 0.72, p < 0.001 respectively), and, in 15 non-diabetic subjects, correlated inversely with insulin sensitivity as measured by a euglycaemic clamp (r = -0.66,p < 0.01). Thus, Beta-cell function needs to be interpreted in relation to obesity/insulin resistance and, taking obesity into account, only 4 of 21 diabetic patients had Betacell function (G-I vector slope) in the non-diabetic range. The fasting plasma glucose in the diabetic subjects correlated inversely with the obesity-corrected G-I and G-C vector slopes (partial r = -0.57, p < 0.01 and -0.86, p < 0.001, respectively). The insulin or C-peptide response to the glucose infusion provides a direct empirical measure of the Beta-cell function, which can be interpreted in relation to obesity or to insulin resistance to assess underlying pancreatic responsiveness.
A simple, easily applicable measure of Beta-cell function is necessary for epidemiological studies of diabetes or for monitoring the development of the disease. The hyperglycaemic clamp [1] provides the most reliable method for assessing pancreatic function but requires too great an investment of resources for most medium and large scale studies. Simpler tests, though commonly used, are less satisfactory. The oral glucose tolerance test cannot easily be used to assess Beta-cell function, due to the complex interaction of increasing and then decreasing glucose and insulin concentrations, large inter-individual variation [2, 3] , and the interference of gastro-intestinal factors such as variable glucose absorbtion rates and 'incretin' effects [4] . The intravenous glucose tolerance test (IVGTT) provides a supraphysiological short-term stimulus to insulin secretion and a 'first phase' insulin response which can be precisely measured, but this is virtually completely suppressed by only mild levels of hyperglycaemia [5] and its relevance to everyday function is uncertain. The 'second phase' insulin response of the IVGTT is difficult to interpret as it is a function of varying glucose concentrations which are themselves dependent on the first phase insulin secretion and insulin sensitivity. Beta-cell function can be assessed from the IVGTT using a minimal model [6] , but 23 samples need to be taken over 3 h, and interpretation requires complex computer program manipulation of the data [7] . Non-glucose stimuli, such as amino-acids (e. g. arginine) or hormones such as glucagon or isoproterenol may be used in the assessment of pancreatic function, but pancreatic responses to these are relatively preserved in diabetes cell function without the use of a model, we show that glucose, insulin and C-peptide changes during the 5 mg. kg IBW-1. min-1 glucose infusion generate empirical linear pancreatic dose response relationship (here termed the glucose-insulin (G-I) and gtucose-C-peptide (G-C) 'vectors'), which may be used to predict an individual's response to a 12 mmol/1 hyperglycaemic clamp. In addition, we show that the vectors can be described by a single variable, the vector slopes, which correlate closely with the estimate of Beta-cell function, %B, derived from the mathematical model with either CIGMA or HOMA assessment. The relationship between the vector assessmerit of Beta-cell function in non-diabetic and Type 2 (non-insulin-dependent) diabetic subjects and their obesity has been studied. Although Type 2 diabetic patients have impaired pancreatic function, a relationship between Beta-cell function, obesity and insulin sensitivity is preserved, so that the G-I or G-C vector slopes need to be interpreted in relation to obesity or to a measure of insulin sensitivity to assess the underlying pancreatic responsiveness in a patient.
Subjects and methods
due to glucose potentiation [8] and assessment of underlying Beta-cell responsiveness requires clamping at different glucose levels [9] .
These tests of Beta-cell function are far removed from the normal physiological demands on the Beta-cell. In contrast, a constant glucose infusion, producing changes in glucose and insulin concentrations in the physiological postprandial range, has provided a basis for both Beta-cell function and insulin sensitivity, interpreting the glucoseinsulin feedback cycle with the aid of a structural mathematical model. The model incorporates Beta-cell function (%B) and insulin sensitivity (% S) variables defined in relation to a standard non-obese non-diabetic population, and predicts glucose, insulin and C-peptide concentrations for any combination of % B and %S in either steadystate, fasting conditions ('homeostasis model assessment': HOMA) [10] or after 60 min of a 5 mg.kg ideal body weight (IBW)-I. min-~ intravenous glucose infusion, ('continuous infusion of glucose with model assessment': CIGMA) [11] . Thus, in any individual, plasma glucose and either insulin or C-peptide concentrations measured either fasting or after the glucose infusion can be used to assess Beta-cell function and insulin sensitivity by comparison with the model which indicates the values of % B and % S which would be expected to give the patient's values.
Although mathematical modelling is a powerful technique used routinely in the physical sciences, its application to clinical situations has often been regarded with suspicion. The model assumes that glucose stimulated Beta-cell function may be described by a function applicable to both basal and glucose stimulated conditions. In diabetes, a Beta-cell Vm~x deficit is modelled as affecting both first and second phase responses, for which there is experimental support [12] . In order to validate these concepts and to provide a direct means of assessing BetaSubjects Protocol 1 -glucose infusion. The characteristics of the glucose-insulin and glucose-C-peptide vectors were studied in 87 continuous 90-rain 5 rag-kg IBW-~-min -~ glucose infusions in 28 non-diabetic and 21 Type 2 diabetic subjects (38 subjects had two glucose infusions). All diabetic subjects, including those in protocols 2, 3 and 4, below, had presented with fasting plasma glucose values greater than 7.8 mmol/1 on diagnosis. The relationship between the vector slopes and obesity and fasting plasma insulin and C-peptide were studied in the first of the two glucose infusions in each subject. None of the diabetic subjects was on any hypoglycaemic medication before these tests and had been on a weight-maintaining diet for at least one month before being studied. ClinicaI details of the subjects are presented in Table 1 .
Protocol2 -glucose infusion followed by hyperglycaemic clamp.
Twelve non-diabetic subjects and 14 Type 2 diabetic subjects (median fasting plasma glucose 7.6, range 4.0-12.6 mmol/1) were given a continuous 90-rain glucose infusion 5 mg. kg IBW-1. rain-a followed by a 90-rain 12 mmol/l hyperglycaemic glucose clamp. None of the non-diabetic subjects had a family history of diabetes. Their details are presented in Table 2 .
Protocol3 -glucose infusion followed by euglycaemic clamp. In 15 non-diabetic subjects, the constant glucose infusion was followed by a 90-min euglycaemic clamp to assess the relationship between the vector slope and insulin sensitivity. Their details are presented in Table 3 .
Protocol 4 -reproducibility of vector slopes. Twenty-eight subjects (five Type 2 diabetic subjects, five first-degree relatives of Type 2 diabetic subjects and 18 non-diabetic subjects) had repeat tests within 3 months of their first glucose infusion (median 4 weeks, range 0.5 to 13 weeks) to assess reproducibility of their response. Their details are presented in Table 4 .
Physiological tests
a. Glucose infusion. Following a 14-h overnight fast, subjects were given a constant 5 mg-kgIBW-~.min -I glucose infusion by an IMED pump (Abingdon, UK) into an antecubital vein for 90 min. Arterialised blood samples were taken from a distal vein in a heated arm. Four 5-min plasma samples were taken initially and samples were taken at 10-min intervals throughout the infusion, and also at 55 min and 85 min. Samples were assayed for glucose, insulin and Cpeptide b. Hyperglycaemic clamp. Following the constant glucose infusion, plasma glucose levels were stabilised at 12 mmol/1 for 90 rain by means of a variable glucose infusion, the rate of which was determined by 2-rain blood samples assayed for whole blood glucose by YSI glucose analyser (Yellow Springs Instrument Co. Cleveland, Ohio, USA) and an unbiased iterative computer program [13] . During the last 15 min of the hyperglycaemic clamp, four 5-rain blood samples were taken to determine plasma glucose, insulin and C-peptide.
c. Euglycaemic clamps. Following the glucose infusion, subjects had a 90-min 4 pmol-kg IBW-:. rain : insulin infusion, primed by an initial 10 rain at double this rate, and plasma glucose was allowed to fall to 4.5 mmot/1 and was clamped at this level by means of 2-min samples and the glucose clamp program. The mean rate of glucose infusion during the last 20 min of the clamp was divided by the subjects' ideal body weight to give the 'M' value. This was then divided by the mean of four 5-min determinations of plasma insulin at the end of the clamp to give 'M/I', which was used as an index of whole body insulin sensitivity.
Biochemistry
Plasma glucose was determined by a hexokinase method on the Cobas Bio centrifugal autoanalyser (Roche, Welwyn Garden City, UK). Insulin and C-peptide were determined by a charcoal separation immunoassay technique [14] .
Calculations
Glucose-insulin and glucose-C-peptide vectors. Insulin and glucose and C-peptide and glucose values before and during the glucose infusion were plotted against each other ( Fig. 1 ) and assumed to represent segments of glucose-insulin and glucose-C-peptide dose response curves. Linear and quadratic models with insulin as the dependent variable were fitted by the least squares method and tested by stepwise regression. The linear model was chosen to represent adequately the glucose-insulin relationship (see results). The G-I and G-C 'vectors' were defined as the segment of the regression line (determined by all the glucose-insulin or glucose-C-peptide pairs) lying between the mean fasting and the mean 80, 85 and 90-rain glucose values. The regression line may be described by means of two coefficients: the vector slope and the constant term i. e., Insulin = vector slope • glucose + constant.
L ,o~,~ ,.,..," 8 The two coefficients of the resulting linear equations in 54 different individuals were also examined by linear regression analysis.
Because of the linearity of the glucose-insulin and glucose-Cpeptide plots, the slopes of the G-I and G-C vectors may be more simply estimated from their extremities, taken as the mean -10, -5 and 0-rain fasting values and either the mean 50, 55 and 60-min value or the mean 80, 85 and 90-min value with the vector slopes calculated by dividing the 60 or 90-min increments from fasting of insulin or Cpeptide by the corresponding increments in glucose, i.e. 8160/8G60, and ~C60/~G60, or 8190/~G90 and ~C90/8G90.
HOMA and CIGMA %B. Fasting glucose, insulin and C-peptide values were calculated as the mean of three 5-min values and evaluated by reference to the HOMA model. This is a physiologically structured computer model of the glucose-insulin feedback system which predicts fasting glucose, insulin and C-peptide levels based on different combinations of B eta-cell function (% B) and insulin sensitivity (% S). Actual fasting data (glucose and insulin or glucose and C-peptide pairs) can be 'read back' from computer predictions to give %B (HOMA %Bi or %Be respectively). %S values are also generated by this procedure. The ~reading back' process was done by linear interpolation between 18 HOMA model generated lines representing plasma glucose and insulin values for values % B between 5% and 200%.
'One hour' achieved glucose, insulin and C-peptide levels were calculated as the mean of the 50, 55 and 60-min samples after the start of the 5 mg-kg IBW-~. min-1 glucose infusion and evaluated by reference to the CIGMA model. This is a computer simulation of the glucose infusion which predicts one hour achieved glucose, insulin and C-peptide concentrations given differing combinations of %B and %S. As in the HOMA model, actual achieved glucose-insulin and glucose-C-peptide pairs are read back from computer predictions to give % B (CIGMA % Bi and % Be) or % S values.
Estimations of %B, which are derived from point data (either fasting or one hour achieved values) are mathematically independent from the vector slopes which are derived from incremental data during the glucose infusion.
Reproducibility. The standard formula for the standard deviation of duplicate samples was used for repeated determinations of the G-I and G-C vector slopes, ~J(Y.difference2/2N) [2] , was expressed as a percentage of the mean value of the slopes to give the coefficient of variation.
Statistical analysis
Group results are presented as means ( + 1 SD), or in the case of insulin or C-peptide levels and vector slopes, as geometric means (1 SD range), except when otherwise indicated. Except in the context of regression equations, simple correlation was assessed by nonparametric measures (Spearman rank coefficients) to avoid overestimation of coefficients by high or low extreme values. Parametric methods were used for partial correlation. Correction of vector slopes by covariates in non-diabetic and diabetic groups was done using the regression method to obtain the common coefficient. Statistical calculations were performed using the SPSS-X statistical package (Chicago, Ill., USA).
Results

Protocol 1: glucose infusion-hyperglycaemic clamp study
Glucose infusion and hyperglycaemic clamp data. Glucose insulin and C-peptide values in the fasting state, at the end of the constant glucose infusion and at the end of the hyperglycaemic clamp are shown in Table 2 . During the glucose clamps, the intra-individual standard deviation of 491 the ten 2-min samples comprising the last 20-rain period had a median value of 0.20mmol/1 (range 0.08 to 0.82 mmol/1), the intra-individual standard deviation of blood glucose during the penultimate 20-rain period was median 0.19mmol/1 (range 0.05-1.29 mmol/1) and the percent difference in plasma glucose between the mean of the ten samples from the last 20-min period and the mean of the ten samples comprising the previous 20-min period had a median of -0.2% (range -4.9 to 6.4%).
Linearity of G-I plots and assessment of vector slope by linear regression or ratio of increments.
Time-matched glucose and insulin values in 87 glucose infusions were highly correlated using a linear model, with a median correlation coefficient of 0.92 (0.86-0.95 interquartile range). A quadratic model was also tested, but in only 5 of 81 tests did the quadratic model account for more than an extra 10% of the variance (r squared) of the G-I plot when compared to the linear model. Because of the success as well as the shnplicity of the linear model it was adopted to describe the glucose -insulin/C-peptide relationship during the glucose infusion.
The regression method of deriving the vector slope was compared to a simpler incremental method: that of dividing the increment in insulin between mean fasting and mean 80, 85 and 90-min values by the corresponding increment in glucose (~I90/~G90). The regression derived vector slope correlated closely with the incremental derivation, r = 0.97, p < 0.001 in 57 individuals ( Table 5 ). The mean estimate by the incremental method was 102% (1 SD range, 87-127% ) of the corresponding slope calculated by regression. Furthermore, because of the linearity of the vector, its slope may also be derived from any other two points along its length, e. g. the fasting and mean 50, 55 and 60-min points (~I60/~G60), which correlated with the regression derived vector slope, Spearman r;0.94, p < 0.001, 816USGs0 being 85% (75-113%) of the regression derived slope. Thus, a closely correlating estimate of the regression-derived vector slope may be obtained from a shorter, 60-rain infusion.
Linearity of G-C plots and assessment of vector slope by linear regression or ratio of increments. Linear regression
equations (G-Cvectors) were derived from glucose-Cpeptide plots in 87 glucose infusion tests in 56 individuals. The median linear correlation coefficient was 0.95 (interquartile range 0.91-0.97). A quadratic model increased the value of r 2 by more than 10% in only 14 cases, and hence a linear model of the G-C plots was used as an adequate representation of the G-C relationship during the 90-rain glucose infusion.
The vector slope derived by regression correlated closely with the slopes calculated as ~C90/~G90 as 8C60/8G~0 (Spearman r = 0.99 and 0.95, p < 0.001 respectively). The G-C vector slopes calculated by ~C90/~G90 and 5C60/~G60 were 103% (94-114%) and 79% (58-108%) of the corresponding regression derived values.
G-I and G-C vector slope -constant-term correlation.
In any individual, the regression line through the G-I plot may be described by two coefficients, 
where It and Gt represent plasma insulin and glucose at any time t during the constant infusion. An analogous equation with different coefficients represents the G-C vector. In 57 individuals (21 Type 2 diabetic and 28 non-diabetic subjects and eight first-degree relatives of Type 2 diabetic subjects), there was a close linear correlation between the G-I vector slope and the constant term (r = 0.99, p < 0.001) (Fig.2a) , the relationship between the two coefficients being described by the equation, While the vector slopes and the constant term in equation 1 are coefficients of individual vectors, p~ and qi for G-I vectors (equation 2) and pc and qc for G-C slopes (equation 3) are essentially population parameters defining the relationship between the two coefficients in any individual. Within the limits of the accuracy of this observation, these population parameters may be used in an individual to calculate the constant term in equation 1given the slope of that individual's vector. Thus, the vector slopes alone are sufficent to describe the empiricalpancreatic glucose response relationship during the glucose infusion.
Since, in any individual, insulin levels both in the fasting state and during the glucose infusion are related to glucose 493 levels in a simple linear fashion by the G-I vector (equation 1), and, in a wide range of individuals, the G-I vector slopes were found to be linearly related to the vector positions (equation 2), these two relationships may, in theory be combined to give an expression for deriving the vector slope from any time point, within the confines of the accuracy of the population parameters pi and % vector slope = (It -qi)/(Gt + Pi)
i. e. in theory the vector slope may be determined by any point along the dose -response segment, for example fasting values (though this would be increasingly inaccurate as the point approached an insulin level of qi and a glucose level of p~) or values at 60 min or 90 min. A similar argument may be applied to the G-C vector slopes. The existence of 'population parameters' Pi and qi, or Pc and qo gives rise to certain theoretical predictions which are testable empirically (see appendix).
G-I plots and prediction of clamp insulin levels. In 48 sep-
arate glucose infusion-hyperglycaemic clamp tests in 28 individuals the G-I vectors were used to predict the actual plasma insulin acheived at the end of the 90-min hyperglycaemic clamp. In most cases this was done by extrapolating the vector to the clamp glucose concentration (12.2 +_ 1.0 mmol/1). In some diabetic subjects, however, plasma glucose during the constant glucose infusion rose higher than this and the predicted response was obtained by interpolation of the vector at the clamp glucose level. The correlation between actual and predicted insulins was high (Spearman r = 0.94, p < 0.001) (Fig. 3a) (in 20 clamps in non-diabetic subjects r = 0.84 p < 0.001, in 27 clamps in diabetic subjects r = 0.97 p < 0.001). Since the difference between predicted and actual clamp insulin concentration increased with the insulin level, logarithmic transformation was used to examine their relationship. Mean predicted levels represented 70.3% + 4.3% SEM of actual levels, (one SD residual range 54-90%, p < 0.001).
G-C plots and prediction of clamp C-peptide levels.
In 46 clamps in 28 individuals, the G-C vectors predicted C-peptide levels at the end of the hyperglycaemic clamp with a correlation coefficent of 0.98, p < 0.001 (Fig. 3 b) .
(In 19 clamps in non-diabetic subjects r = 0.91, p < 0.001, in 27 clamps in diabetic subjects r = 0.98 p < 0.001). In contrast with predictions from G-I vectors to clamp insulin levels, errors of prediction from G-C vectors did not increase with clamp C-peptide levels, and predicted levels were consistently 0.31 ( _+ 0.08) nmol/1 lower than actual clamp C-peptide levels (residual SD = 0.20 nmol/1).
Comparison between G-I and G-C vectors and % Beta calculated from the CIGMA model. The G-I and G-C vector
slopes correlated with the model-derived %B values derived from glucose, insulin and C-peptide values after 55 rain of the glucose infusion (CIGMA) (Spearman r = 0.92 and 0.94 respectively, p < 0.001, Table 5 ).
Comparison between G-I and G-C vectors and % Beta calculated from HOMA model The G-I and G-C vector
slopes correlated with the model-derived %B values derived from fasting glucose, insulin and C-peptide values Body mass index (kg/m 2)
Fig.& (a) Glucose-insulin (G-I) and (b) glucose-C-peptide (G-C) vector slopes plotted against BMI in 23 non-diabetic (open squares) and 21 diabetic subjects (closed circles)
(HOMA) (Spearman r=0.86 and 0.67, p <0.001) ( Table 5) .
Reproducibility of G-I and G-C slopes.
The mean of the differences between first and second estimations of G-I slopes were not significantly different from zero ( -0.86 + 1.4 SEM pmol/mmol). G-I slopes from second tests are plotted against first test results in Figure 4 , the insert showing the differences plotted against the mean of the two estimations (mean 25.4 pmol/mmol, range 2.4-97.1 pmol/mmol). The coefficient of variation of G-I slopes was 21%. This would be due to variation from true physiological variability on the one hand, and to variability arising from assay techniques, sampling and storage etc, on the other. The derivation of the vector slope by the least squares method allows an estimation of the standard error for each G-I slope. The median percent standard error of the G-I slopes on all 28 tests was 11.2%. Mean differences between first and second estimations of G-C slopes were not significantly different from zero ( -0.013 + 0.009 SEM nmol/mmol). G-C slopes from second tests are plotted against the first test and differences plotted against the mean of the two estimations (mean 0.196 pmol/mmol, range 0.002-0.670 nmol/mmol) in Figure 4 . The coefficient of variation of G-I slopes was 16%. The median percentage standard error of the G-I slopes on all 28 tests was 8.3%.
G-I and G-C vectors in non-diabetic and Type 2 diabetic
subjects. G-I and G-C vector slopes were calculated in the 28 non-diabetic and 21 Type 2 diabetic subjects. In both groups the distributions of insulin, glucose and vector slopes were positively skewed, and statistics were performed on logarithmically transformed data. The geometric mean G-Islopes (+ISD range) were 28.4pmol/mmol (14.2-57.0) and 7.7 pmol/mmol (3.2-19.0), respectively, (p <0.001), and G-Cslopes were 0.254 nmol/mmol (0.170-0.380) and 0.069 nmol/mmol (0.029-0.165) p < 0.001, in the non-diabetic and diabetic subjects. However, although there was a significant difference between the geometric means of the two groups, there was a considerable overlap between individual values, with 11 of 21 G-Ivector slopes and 6 of 21 G-C vector slopes in diabetic subjects falling within the normal range, defined as mean + 1.96 SD of the normal group.
Relation of G-I and G-C vectors to obesity.
In 28 nondiabetic subjects with no family history of diabetes, there was a significant linear relationship between Beta-cell function expressed as log G-I vector slope and obesity (BMI) (Fig. 5 a) , thus ated by fasting glucose levels since there was no independent correlation between fasting glucose and either the G-I or G-C vectors or BMI in the non-diabetic subjects. In 21 Type 2 diabetic subjects, there were significant and opposing partial correlations between log G-I vector slope and BMI (partial r = 0.50,p < 0.05) and fasting plasma glucose (FPG) (partial r = -0.57,p < 0.01), thus, Logt0 (G-I Vector slope) --0.060 ( + 0.020) x BMI -0.090 ( + 0.028) x FPG -0.03 ( + 0.56), multiple r = 0.70, p < 0.01. Multiple regression against both %IBW and FPG was possible because there was no significant correlation between these two independent 495 variables (r = 0.07, NS). The coefficients of % IBW in the diabetic subjects did not differ significantly from the equivalent coefficient in the non-diabetic group. Correcting for obesity as covariate, only 4 of 21 G-I vector slopes fell within 2 residual standard deviations of the mean value for non-diabetic subjects (Fig. 5 a) . G-I vector slopes corrected for obesity are plotted against fasting plasma glucose in Figure 6 a.
In the non-diabetic subjects there was no significant relationship between Log G-C vector slope and %IBW, but in the diabetic subjects, opposing partial correlation coefficents between log G-C vector slope and BMI and FPG were significant (partial r = 0.63, p < 0.01 and partial r = -0.86, p < 0.001) with a multiple regression equation of Log10 (G-C Vector slope) = 0.045 ( + 0.013) x BMI -0.14 ( + 0.02) x FPG -1.33 ( + 0.36), multiple r = 0.88, p < 0.001. G-C vector slopes corrected for obesity are plotted against fasting plasma glucose in Figure 6b .
Relation of G-I and G-C vectors to fasting insulin and C-peptide concentrations.
In the non-diabetic subjects, a significant linear relationship was found between the G-I vector slope and log fasting plasma insulin (FPI), LOG~0 (G-I vector slope) = 0.79 ( _+ 0. In 21 Type 2 diabetic subjects, there were significant and opposing partial correlations between log G-I vector slope and log FPI (partial r = 0.58, p < 0.01) and FPG, (partial r = -0.66, p < 0.01), the multiple regression equation expressing these relationships being, When the correlation between the vector slopes and FPI and FPC were taken into account, the overlap between normal and diabetic groups was much reduced, with only 4 of 21 G-I slopes and 3 of 21 G-C slopes in diabetic subjects falling within 2 residual standard deviations of the respective normal ranges (Fig. 7) .
Vector slope and insulin sensitivity. constant glucose infusion, the median CV (standard deviation/me an in each individual) of infusion rates in the last 10 2-min samples (last 20m in) was 10.5% (range2.9-18.6% ), the median CV of the previous ten 2-min samples (penultimate 20 min) was 10.1% (range 1.1-32% ) and the median percent difference in mean infusion rates in these two periods was 2.3% (range -30 to 30%). The median CV (standard deviation/mean in each individual) of blood glucose in the last ten 2-min samples (last 20 min) was 0.09 mmol/1 (range 0.04-0.17), the median CV of the previous ten 2-min samples (penultimate 20min) was 0.09 mmol/1 (range 0.05-0.23) and the median percent difference in mean infusion rates in these two periods was 2.6% (range-0.2 to 6.4%). Insulin levels were 223 (187-274) pmol/1.
G-I vector slopes were significantly negatively correlated to insulin sensitivity as measured by total body glucose requirement divided by insulin concentration (M/I), r = 0.66,p < 0.01 (Fig.8) .
Discussion
During the 90 min of the glucose infusion in normal subjects, plasma glucose traverses the physiological postprandial range, with an increment of approximately 4 mmol/1, and therefore insulin and C-peptide changes reflect a clinically relevant pancreatic response to glucose. The linearity of the glucose-insulin and glucose-C-peptide plots is an empirical finding. It arises in part because the rapid "firstphase" insulin response at the beginning of the glucose infusion, succeeded by a slower rise, is matched by a similar pattern in glucose levels, due to the combined effects of slow equilibration in a multi-compartmental system and the progressive fall in the rate of glucose appearance in the system as hepatic glucose output is suppressed [15] . However, after the first 10 min of the infusion, the rise in plasma glucose is gradual and unidirectional and is matched by the rise in plasma insulin or C-peptide. The plots derived by linear regression between fasting and 60 or 90-min values have been termed glucose-insulin and glucose C-peptide 'vectors' and the slopes have been shown to represent the Beta-cell dose-response curve.
G-I and G-C vectors can be extrapolated to predict insulin and C-peptide levels that would be achieved at a glucose concentration of 12 mmol/1. When compared with actual plasma insulin or C-peptide response to a subsequent 90-min hyperglycaemic clamp, the predicted values showed a high degree of correlation with G-I plots, which predicted a consistent 70% of clamp insulin values, and G-C plots which predicted clamp C-peptide levels with a small constant absolute amount over a wide range of pancreatic function. Some underestimation of actual clamp values would be expected, due to the progressive rise seen in insulin and C-peptide levels during the maintained hyperglycaemia of a clamp [1] , and this underestimation would be expected to increase with the length of the clamp. However, the relationship between the predicted and actual responses is simple, as demonstrated in Figure 3 . The greater difference between actual and predicted clamp levels for insulin than C-peptide may reflect the non-linearity of insulin removal [16] [17] [18] . However, the consistency of the predictions validates the G-I and G-C plots as representations of the glucose responsiveness of the Beta-cell in the physiological range. The plots may be regarded as empirical linear dose-response plots. As the Beta-cell secretion-stimulus curve is sigmoidal in shape [19] [20] [21] [22] [23] [24] it is not clear at first sight why a linear dose -response relationship was obtained. However, studies of the glucose-insulin dose response curves generated from repeated glucose infusions are approximately linear between 5-12 mmol/1 [19] , and the normal basal glucose value probably lies near the point of infiexion of the sigmoidal curve [25] .
The straight-line relationship may be represented by two coefficients, the slope of the line and a constant term representing its position with respect to the glucose axis. However, in a large group of individuals with widely differing pancreatic responsiveness, the coefficients were highly correlated and either may be derived from the other, within the bounds of experimental error. In other words, only one coefficient is necessary to describe Betacell function, and we have used the vector slope rather than the constant term as it is more intuitively representative of Beta-cell function. The linearity of the plots also means that their slopes may be derived simply from the ratio of incremental insulin or C-peptide and incremental glucose obtained from samples taken from fasting and from the end of a 60 or 90-min glucose infusion, and this simple method of calculation correlated closely with the regression based method.
The insulin and C-peptide vector slopes are simple, empirically derived measures of Beta-cell function, as expressed in the response of peripheral plasma insulin or Cpeptide to glucose. Several more complex measures of Beta-cell function exist, including the hyperglycaemic clamp [1] , the minimal model interpreted IVGTT [7] , and the glucose potentiation slope [8] . Comparison of the vector slopes with the latter two is outside the scope of this study. However, the vector slopes correlate closely with the results of hyperglycaemic clamping, which, although reflecting the resultant of insulin and C-peptide secretion and clearance rates rather than pure glucose responsiveness at the cellular level, provides the 'gold standard' measure of effective pancreatic response to glucose. The glucose clamp is an intensive procedure limited to experienced research departments and small-scale studies. On the other hand estimation of the vector slope from a simple continuous glucose infusion is a much easier and cheaper procedure, and thus more suited to assessing Beta-cell function in medium and large-scale studies.
The reproducibilities of the G-I and G-C vectors, as assessed by coefficients of variation, compare favourably with that of either glucose [2] or insulin [3] concentrations during the OGTT, and particularly with the insulin/glucose ratio measured 1 h after oral glucose [3] , even though the latter was repeated after only a 48 h interval. The total intra-individnal variation assessed by the coefficient of variation of the G-I and G-C vector slopes in duplicate tests was 21% and 16% respectively. This will derive from both true physiological variation on the one hand, and the oversimplification of the linear assumption and technical errors such as assay imprecision and sampling and storage variability, on the other. This may be assessed by the median percent standard errors of vector slopes as 12.2 and 10.2% respectively. Though these two estimates of variability are not strictly comparable, they give a qualitative impression of a relatively large contribution from technical errors. It is likely that the reproducibility of the G-I vector slopes will improve with technical improvements in the insulin assay.
The success of a single variable in describing the pancreatic response in the physiological glucose range is possibly surprising, as insulin secretion in vitro and in vivo consists of two 'phases', the first phase being said to be particularly impaired in Type 2 diabetes [5] . However, this conclusion was based on studies using an IVGTT, in which an impaired first phase leads to later hyperglycaemia which provides a greater stimulus to the second phase. In studies which attempt to standardise the second phase glucose stimulus such as the bolus-infusion studies of Cerasi et al. the dose response caracteristics of the two phases of insulin secretion tended to vary in parallel [19] . This can be achieved more successfully using glucose clamping technology, and during stepped hyperglycaemic clamps at different glucose levels, both phases were similarly impaired in mild Type 2 diabetic subjects [12] . Thus, a reduced G-I or G-C vector slope represents a global decrease in the Beta-cell response.
The slope of the glucose-insulin vector is linearly related to its position over a wide range of non-diabetic and diabetic individuals implying that the vector slope may be calculated from the insulin and glucose values at any point, from equation 4. This is an empirical confirmation of the assumptions used in the HOMA-CIGMA structural mathematical model which generates Beta-cell and insulin sensitivity measurements from plasma glucose and insulin or C-peptide concentrations at single time points.
These measures, derived from plasma glucose, insulin and C-peptide concentrations either in the fasting steadystate (HOMA) [10] or after an ideal body weight standardised glucose infusion (CIGMA) [11] , are mathematically independent from the vector slopes, and experimentally independent from the results of the hyperglycaemic clamp. However, there is a high degree of correlation between the HOMA and the CIGMA derived %B, 497 the vector slopes and the hyperglycaemic clamp insulin and C-peptide concentrations. This supports the HOMA-CIGMA model assumption that the plasma glucose is the main Beta-cell regulator in both fasting and glucosestimulated states [26, 27] .
The Beta-cell response to the glucose infusion can be expressed either as the empirical vector slope or as the model (CIGMA) derived % B. The vector slopes have the advantage of ease of calculation and model free evaluation, whereas the direct expression of %B in terms of a normal reference population may assist interpretation of the result. Model assessment of the glucose, insulin and Cpeptide changes during the glucose infusion also provides a measure of insulin sensitivity as well as Beta-cell function.
The G-I and G-C vector slopes in non-diabetic and Type 2 diabetic subjects confirm marked impairment in Beta-cell responsiveness in the diabetic group taken as a whole. The two groups show some overlap, which at first sight suggests that approximately half of these mild Type 2 diabetic subjects have Beta-cell responsiveness in the normal range, albeit in the context of a higher ambient glucose concentration. However, both non-diabetic and diabetic subjects show a significant association between G-I vector slope and obesity expressed as %ideal body weight. Taking this into account, only 4 of 21 relatively mild diabetic subjects had vector slope values in the normal range. Bagdade et al. [28] reported an association in normal subjects between the fasting plasma insulin level and the insulin response to an oral glucose tolerance test, and the inverse relationship between Beta-cell function and insulin sensitivity has been noted in several experimental situations [20, 29, 30] . This relationship is reflected in the positive association between vector slope and fasting plasma insulin, and this is supported directly by the negative correlation between vector slope and insulin sensitivity as assessed by the euglycaemic clamp. These results confirm the importance of taking the prevailing degree of insulin sensitivity into account in the assessment of Beta-cell function in both non-diabetic and diabetic subjects [30] and this can be done either with a measure such as the fasting plasma insulin or from the degree of obesit), as that is a major determinant of insulin resistance. On theoretical grounds one might expect a direct measure of insulin resistance, the fasting plasma insulin, would be the better index, but the assay imprecision at low fasting levels and the pulsatility of basal insulin secretion [31] probably make current measurements sub-optimal, so that measurement of obesity becomes a better indirect assessment of insulin resistance in the general population. The negative association between the obesity-corrected vector slopes and fasting plasma glucose in the diabetic subjects underlines the fact that the severity of diabetes is linked to the severity of Beta-cell function. Nevertheless, the obesity-corrected vector slope remained subnormal in the majority of the diabetic subjects who, on dietary management, had managed to reduce their fasting glucose levels to the normal range.
In summary, insulin and C-peptide concentrations during a low dose glucose infusion, when related to simultaneous glucose concentrations, generate an empirically li-near relationship which may be taken as a measure of the Beta-cell glucose dose response, as it predicts the insulin levels achieved by the hyperglycaemic clamp, the 'gold standard' clinical test of Beta-cell function. The characteristics of this 'vector' may be summarised in a single variable, the 'vector slope' which may be used to describe Beta-cell function in the physiological range. The vector slope agrees closely with the Beta-cell coefficient generated by the CIGMA model. The glucose infusion test is suited to the assessment of Beta-cell function in large populations or prospective studies. The measured Betacell function is affected by the degree of obesity and the prevailing insulin resistance. The underlying characteristic Beta-cell function of a patient can be discerned by its evaluation with respect to the prevailing insulin resistance.
